Determination of febuxostat in human plasma using ultra-performance liquid chromatography tandem mass spectrometry

Drug Testing and Analysis

Volumn 5, Issue 6, 2013, Pages 492-499

  Lukram, Ojikumar ^a   Parmar, Shivaji ^a   Hande, Amit ^a  

^a Division of Centaur Pharmaceuticals Pvt Ltd   (India)

Author keywords

Febuxostat; Human plasma; Trandolapril; UPLC MS MS

Indexed keywords

BIOCHEMISTRY; COLUMN CHROMATOGRAPHY; HIGH PRESSURE LIQUID CHROMATOGRAPHY; PARTICLE SIZE; PLASMA (HUMAN); SOLVENT EXTRACTION;

FEBUXOSTAT; HUMAN PLASMAS; INTERNAL STANDARDS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; LIQUID-LIQUID EXTRACTION; SENSITIVE LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; TRANDOLAPRIL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRA-PERFORMANCE LIQUID CHROMATOGRAPHY-MS/MS;

MASS SPECTROMETRY;

ACETONITRILE; FEBUXOSTAT; FORMIC ACID; TRANDOLAPRIL;

ARTICLE; BIOEQUIVALENCE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; HIGH THROUGHPUT SCREENING; HUMAN; LIMIT OF QUANTITATION; LIQUID LIQUID EXTRACTION; PARTICLE SIZE; PRIORITY JOURNAL; QUALITY CONTROL; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 84879025226     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.420     Document Type: Article

References (27)

1. M. A. Becker, R. Schumacher, R. L. Wortmann Jr, P. A. MacDonald, D. Eustace, W. A. Palo, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New Engl. J. Med. 2005, 353, 2450.
2. L. W. Moreland Febuxostat - Treatment for Hyperuricemia and gout? New Engl. J. Med. 2005, 353, 2505.
3. K.-H. Yu Febuxostat: A Novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in Gout. Recent Pat. Inflamm. Allergy Drug Discov. 2007, 1, 69.
4. K. Okamoto, B. T. Eger, T. Nishino, S. Kondo, E. F. Pai, T. Nishino An extremely potent inhibitor of xanthine oxidoreductase crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J. Biol. Chem. 2003, 278, 1848.
5. Y. Takano, K. Hase-Aoki, H. Horiuchi, L. Zhao, Y. Kasahara, S. Kondo, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci. 2005, 76, 1835.
6. H. Horiuchi, M. Ota, M. Kobayashi, H. Kaneko, Y. Kasahara, S. Nishimura, et al. A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats. Res. Commun. Mol. Path. 1999, 104, 307.
7. Y. Osada, M. Tsuchimoto, H. Fukushima, H. K. Takahashi, S. Kondo, M. Hasegawa, et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur. J. Pharmacol. 1993, 241, 183.
8. S. Hoshide, S. Nishimura, S. Ishii, K. Matsuzawa, N. Saito, T. Tanaka Drug Metab. Rev. 2000, 32, 2269.
9. R. Khosravan, M. Mayer, B. Grabowski, L. Vernillet, J.-T. Wu, N. Joseph-Ridge Febuxostat, a non-purine selective inhibitor of xanthine oxidase-effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety [abstract]. American college of rheumatology 2004 annual scientific meeting. Arthritis Rheum. 2004, 50(suppl 9): S337.
10. R. Khosravan British J Clin Pharmacol 2007 DOI: 10.1111/j.1365-2125.2007.03016.x
11. R. Khosravan, N. Cooper Quantification of uric acid, xanthine and hypoxanthine in human serum by HPLC for pharmacodynamic studies. J. Chromatogr. B 2006, 837, 1.
12. Z. Cong, W. Shao-Jie, M. Rong-li, M. Ping, Z. Tian-hong Determination of content of febuxostat and its related substances by HPLC. J. Shenyang Pharmaceutical University. 2010, 27(8), 648-651.
13. M. H. Kadivar, P. K. Sinha, D. Kushwah, P. Jana, H. Sharma, A. Bapodra Study of impurity carryover and impurity profile in febuxostat drug substance by LC-MS/MS technique. J. Pharm. Biomed. Anal. 2011, 56, 749.
14. 14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects. J. Clin. Pharmacol. 2011, 51, 189.
15. M. D. Mayer, R. Khosravan Am. J. Therap. 2005, 12, 2.
16. M. Kalovidouris, S. Michalea, N. Robola, M. Koutsopoulou, I. Panderi Ultra-performance liquid chromatography/tandem mass spectrometry method for the determination of lercanidipine in human plasma. Rapid Commun. Mass Spectrom. 2006, 20, 2939.
17. S. Caia, T. Huoa, W. Fengb, L. Chena, F. Qina, F. Li Quantitative determination of mitiglinide in human plasma by ultra-performance liquid chromatography/electrospray ionization tandem mass spectrometry. J. Chromatogr. B 2008, 868, 83.
18. M. Mezcua, A. Aguer, J.L. Liberia, M.A. Cortes, B. Bago, A.R. Fernandez-Alba, et al. Application of ultra performance liquid chromatography-tandem mass spectrometry to the analysis of priority pesticides in groundwater. J. Chromatogr. A 2006 DOI: 10.1016/j.chroma.2006.01.024.
19. H. Huang, Y. Zhang, R. Yang, X. Tang Determination of baicalin in rat cerebrospinal fluid and blood using microdialysis coupled with ultra-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 2008, 874, 77.
20. M. E. Swartz Ultra performance liquid chromatography: Tomorrow's HPLC technology today. Tomorrow's HPLC Technol. Today Lab Plus Int. 2004, 3, 6.
21. J. Castro-Perez, R. Plumb, J. H. Granger, I. Beattie, K. Joncour, A. Wright Increasing throughput and information content for in vitro drug metabolism experiments using ultra-performance liquid chromatography coupled to a quadrupole time-of-flight mass spectrometer. Rapid Commun. Mass Spectrom. 2005, 19, 843.
22. Y. Yang, C. C. Hodges Assay transfer from HPLC to UPLC for higher analysis throughput. Separation Sci. Redefined 2005, 31.
23. V. K. Gupta, O. Lukram Simultaneous determination of ramipril, ramiprilat and telmisartan in human plasma using liquid chromatography tandem mass spectrometry. Talanta 2011, 83, 709.
24. Food and Drug Administration. FDA Guidance for Industry: Bioanalytical Method Validation. Rockville, MD : US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2001.
25. Guideline on the Investigation of Bioequivalence, European Medicines Agency PMP/EWP/QWP/1401/98/Rev. 1/Corr). London, 20 January 2010. Available at: ttp://www.ema.europa.eu/docs/en GB/document library/Scientific guideline/2010/01/WC500070039.pdf [21 January 2011].
26. Guideline on Validation of Bioanalytical Methods, (Draft), European Medicines Agency (EMEA/CHMP/EWP/192217/2009). London, 19 November 2009. Available at: http://www.ema.europa.eu/docs/en GB/document library/Scientific guideline/2009/12/WC500018062.pdf [21 January 2011].
27. C.T. Viswanathan, S. Bansal, B. Booth, A.J. DeStefano, M.J. Rose, J. Sailstad, et al. Workshop/conference report - quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays. AAPS J. 2007, 9, E30.